CA2577009C - Ceramide derivatives as modulators of immunity and autoimmunity - Google Patents

Ceramide derivatives as modulators of immunity and autoimmunity Download PDF

Info

Publication number
CA2577009C
CA2577009C CA2577009A CA2577009A CA2577009C CA 2577009 C CA2577009 C CA 2577009C CA 2577009 A CA2577009 A CA 2577009A CA 2577009 A CA2577009 A CA 2577009A CA 2577009 C CA2577009 C CA 2577009C
Authority
CA
Canada
Prior art keywords
cells
galactosylceramide
alpha
cell
ceramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2577009A
Other languages
English (en)
French (fr)
Other versions
CA2577009A1 (en
Inventor
Steven A. Porcelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of CA2577009A1 publication Critical patent/CA2577009A1/en
Application granted granted Critical
Publication of CA2577009C publication Critical patent/CA2577009C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
CA2577009A 2004-08-27 2005-08-26 Ceramide derivatives as modulators of immunity and autoimmunity Expired - Fee Related CA2577009C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60536204P 2004-08-27 2004-08-27
US60/605,362 2004-08-27
PCT/US2005/030330 WO2006026389A2 (en) 2004-08-27 2005-08-26 Ceramide derivatives as modulators of immunity and autoimmunity

Publications (2)

Publication Number Publication Date
CA2577009A1 CA2577009A1 (en) 2006-03-09
CA2577009C true CA2577009C (en) 2017-05-02

Family

ID=36000590

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2577009A Expired - Fee Related CA2577009C (en) 2004-08-27 2005-08-26 Ceramide derivatives as modulators of immunity and autoimmunity

Country Status (10)

Country Link
US (1) US7772380B2 (enExample)
EP (1) EP1784196B1 (enExample)
JP (3) JP5226311B2 (enExample)
KR (2) KR20120116511A (enExample)
CN (1) CN101010086B (enExample)
AU (1) AU2005280163B2 (enExample)
CA (1) CA2577009C (enExample)
IL (1) IL181054A (enExample)
NZ (1) NZ553320A (enExample)
WO (1) WO2006026389A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
KR20120116511A (ko) * 2004-08-27 2012-10-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체
US8022043B2 (en) * 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
US20100129339A1 (en) * 2005-10-06 2010-05-27 Riken Nkt cell-stimulating agent for administration through upper respiratory tract mucous membrane
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
AU2007269299B2 (en) * 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
WO2008048410A2 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Diagnostic methods and genetic markers for alzheimer disease
WO2008047174A1 (en) * 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
KR100868959B1 (ko) * 2006-12-30 2008-11-17 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
JP2010519274A (ja) 2007-02-21 2010-06-03 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） ＴＮＦおよびα−ガラクトシルセラミドを使用する併用療法
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
US8802098B2 (en) 2007-04-25 2014-08-12 Immurx, Inc. Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
WO2009060305A2 (en) 2007-10-12 2009-05-14 Luigi Panza Analogues of glycolipids useful as immunoadjuvants
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
WO2010027479A2 (en) 2008-09-08 2010-03-11 Children's Medical Center Corporation Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
JP5574432B2 (ja) * 2008-09-11 2014-08-20 独立行政法人理化学研究所 エステル化α−ガラクトシルセラミド類
CN102215864A (zh) 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物
PT2385980T (pt) * 2009-01-08 2018-06-26 Albert Einstein College Medicine Inc Vacinas bacterianas com glicolípidos do tipo ceramida associados à parede celular e utilização dos mesmos
KR20110045545A (ko) * 2009-10-27 2011-05-04 서울대학교산학협력단 신규 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 면역보조용 약학적 조성물
WO2011112889A2 (en) * 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
WO2013007792A1 (en) * 2011-07-14 2013-01-17 Thurgauische Stiftung Für Wissenschaft Und Forschung Novel th2 polarizing compounds
HK1199405A1 (en) 2011-10-27 2015-07-03 Nkt治疗公司 Humanized antibodies to inkt
CA2857226A1 (en) * 2011-11-28 2013-06-06 Uti Limited Partnership Prophylactic compositions for management of microbial infections in patients with brain injury
EP2811831B1 (en) 2012-02-07 2018-04-11 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
KR101969814B1 (ko) * 2012-02-24 2019-04-18 주식회사 진영바이오 글리코실 세라마이드 화합물 및 그 제조방법
JP5933106B2 (ja) * 2012-03-19 2016-06-08 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー 炭水化物−糖脂質共役ワクチン
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
KR102099764B1 (ko) * 2012-04-26 2020-04-10 리가가쿠 겐큐쇼 신규 카르바메이트 당지질 및 그 용도
US9586985B2 (en) * 2012-07-26 2017-03-07 Victoria Link Limited Organic compounds as proantigens for natural killer T cells
US20150224129A1 (en) 2012-10-03 2015-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists
WO2014059220A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
US9764037B2 (en) * 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
NZ710949A (en) * 2013-02-08 2020-02-28 Vaccinex Inc Modified glycolipids and methods of making and using the same
JP6466907B2 (ja) 2013-03-15 2019-02-06 パーキンエルマー・ヘルス・サイエンシーズ・インコーポレイテッドＰｅｒｋｉｎｅｌｍｅｒ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． ライソゾーム病の検査に関する化合物および方法
KR102298172B1 (ko) * 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
CN105461681A (zh) * 2014-09-05 2016-04-06 中国科学院生态环境研究中心 具有抗肿瘤活性的krn7000类似物及合成方法
KR102422375B1 (ko) * 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
KR101589633B1 (ko) * 2014-09-18 2016-02-01 한국과학기술연구원 당세라마이드 유도체 및 이의 제조방법
CN104497064B (zh) * 2014-11-24 2017-10-24 浙江大学 α‑半乳糖神经酰胺新异构体及其合成方法
CN104497065B (zh) * 2014-11-24 2017-10-24 浙江大学 α‑半乳糖神经酰胺新异构体及其用途
CN105384785B (zh) * 2015-11-24 2018-06-19 中国人民解放军第二军医大学 含有半乳糖类脂肪酸衍生物的制备方法及其在医药领域的应用
SG11201808554TA (en) 2016-04-22 2018-11-29 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
WO2017207040A1 (en) 2016-06-01 2017-12-07 Vib Vzw ANTI-CANCER THERAPY USING A LEPTIN ANTAGONIST AND AN iNKT-CELL ACTIVATOR
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
CA3080521A1 (en) 2017-10-27 2019-05-02 Children's Medical Center Corporation Short chain ceramide-based lipids and uses thereof
CA3096398A1 (en) 2018-04-12 2019-10-17 Children's Medical Center Corporation Ceramide-like lipid-based delivery vehicles and uses thereof
CN109701009A (zh) * 2019-01-03 2019-05-03 华中师范大学 疫苗制剂及其应用
KR102146226B1 (ko) * 2019-03-07 2020-08-20 경희대학교 산학협력단 피토세라마이드 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 신경계 자가면역질환의 예방 또는 치료용 조성물
WO2022102557A1 (ja) * 2020-11-12 2022-05-19 国立研究開発法人理化学研究所 擬似糖脂質誘導体並びにその合成中間体、製造方法及び用途
IL305579A (en) * 2021-03-01 2023-10-01 Deciduous Therapeutics Inc Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells
WO2023096715A2 (en) * 2021-10-22 2023-06-01 President And Fellows Of Harvard College Immunomodulatory glycosphingolipids and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
CA2147629C (en) * 1992-10-22 2005-03-22 Koji Akimoto Novel sphingoglycolipids and the use thereof
US6238676B1 (en) * 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5853737A (en) * 1992-12-10 1998-12-29 Brigham And Women's Hospital Method for inducing a CD1-restricted immune response
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
AU683653B2 (en) * 1993-04-15 1997-11-20 Kirin Pharma Kabushiki Kaisha Novel sphingoglycolipid and use thereof
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
CN1222293C (zh) * 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α－糖基神经酰胺的NKT细胞活化剂
JP2004131481A (ja) * 1997-04-10 2004-04-30 Kirin Brewery Co Ltd α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
AU2087799A (en) * 1997-12-31 1999-07-19 Brigham And Women's Hospital Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
BR0211968A (pt) * 2001-08-16 2004-09-28 Daiichi Suntory Pharma Co Ltd Glicolipìdio útil no tratamento de doenças autoimunes e medicamento do mesmo
JP2005533057A (ja) * 2002-06-13 2005-11-04 ニューヨーク・ユニバーシティ 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用
EP1572114A2 (en) * 2002-09-27 2005-09-14 Biomira, Inc. Glycosylceramide analogues
CN100537585C (zh) * 2003-02-14 2009-09-09 阿斯比奥制药株式会社 糖脂衍生物及其制造方法,以及其合成中间体及其制造方法
KR20120116511A (ko) * 2004-08-27 2012-10-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 면역 및 자가면역의 조절제로서의 세라마이드 유도체

Also Published As

Publication number Publication date
NZ553320A (en) 2011-02-25
EP1784196B1 (en) 2016-12-21
JP5870327B2 (ja) 2016-02-24
WO2006026389A3 (en) 2006-05-26
JP5226311B2 (ja) 2013-07-03
CA2577009A1 (en) 2006-03-09
EP1784196A4 (en) 2012-05-30
CN101010086A (zh) 2007-08-01
KR20070023825A (ko) 2007-02-28
AU2005280163B2 (en) 2011-11-24
IL181054A0 (en) 2007-07-04
JP2008511634A (ja) 2008-04-17
IL181054A (en) 2013-10-31
US7772380B2 (en) 2010-08-10
AU2005280163A1 (en) 2006-03-09
CN101010086B (zh) 2013-05-29
KR101377116B1 (ko) 2014-03-24
JP2015007125A (ja) 2015-01-15
KR20120116511A (ko) 2012-10-22
EP1784196A2 (en) 2007-05-16
JP2012211182A (ja) 2012-11-01
US20060052316A1 (en) 2006-03-09
WO2006026389A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
CA2577009C (en) Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) Ceramide derivatives as modulators of immunity and autoimmunity
US8163290B2 (en) Glycolipids and analogues thereof as antigens for NKT cells
US20090233875A1 (en) Glycolipids and analogues thereof as antigens for nk t cells
AU2013293646B2 (en) Organic compounds
KR102167438B1 (ko) 변형된 당지질들 및 이들을 제조하고 사용하는 방법들
TW202110459A (zh) 皂苷共軛物及含其之疫苗或藥物組合物
WO2021255287A1 (en) Phytosphingosine derivatives as adjuvants in immune stimulation
NZ613614B2 (en) Sphingoglycolipid compounds and uses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831